Now that you know Pseudomonas aeruginosa can hide within the lungs, progress, and threaten the way you’re feeling, it may be time to talk to your doctor or someone on your cystic fibrosis (CF) care team.

Download a doctor discussion guide now or build your personalized guide below.

My top conversation starters:

Please, select question for discussion
The field is required

What questions below are most important to you? Click the plus sign on as many of the questions as you want to build your doctor discussion guide.

What medications are critical for me to keep feeling my best?
I’m concerned that Pseudomonas aeruginosa could be hiding in my lungs.
Managing multiple treatments for CF along with a busy lifestyle is hard. How do others you know do it?
Are the CF treatments I’m taking now protecting me from Pseudomonas aeruginosa?
I’m having more respiratory symptoms; what should I do?
I haven’t been taking my inhaled antibiotics. Can you help me get back on track?
Does chronic Pseudomonas aeruginosa ever go away?
I’m feeling better with my other CF treatments, so why do I need to take my treatment for Pseudomonas aeruginosa?
What could happen if I don’t take my treatment for Pseudomonas aeruginosa?
If I’ve had an exacerbation, do I need to restart my inhaled antibiotics?
References
  • Pseudomonas. Cystic Fibrosis Foundation website. Accessed June 1, 2021. https://www.cff.org/Life-With-CF/Daily-Life/Germs-and-Staying-Healthy/What-Are-Germs/Pseudomonas/
  • Tramper-Stranders GA, van der Ent CK, Wolfs TFW. Detection of Pseudomonas aeruginosa in patients with cystic fibrosis. J Cyst Fibros. 2005;4 Suppl 2:37-43.
  • Cystic fibrosis. US National Library of Medicine website. Updated August 18, 2020. Accessed June 1, 2021. https://medlineplus.gov/download/genetics/condition/cystic-fibrosis.pdf
  • Moore JE, Mastoridis P. Clinical implications of Pseudomonas aeruginosa location in the lungs of patients with cystic fibrosis. J Clin Pharm Ther. 2017;42(3):259-267. doi:10.1111/jcpt.12521
  • Hansen CR, Pressler T, Høiby N. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. J Cyst Fibros. 2008;7(6):523-530. doi:10.1016/j.jcf.2008.06.009
  • Stuart B, Lin JH, Mogayzel PJ Jr. Early eradication of Pseudomonas aeruginosa in patients with cystic fibrosis. Paediatr Respir Rev. 2010;11(3):177-184. doi:10.1016/j.prrv.2010.05.003
  • Cystic Fibrosis Foundation. 2019 Patient Registry Annual Data Report. Bethesda, MD: Cystic Fibrosis Foundation; 2019. Accessed June 1, 2021. https://www.cff.org/Research/Researcher-Resources/Patient-Registry/2019-Patient-Registry-Annual-Data-Report.pdf
  • Cunningham JC, Taussig LM. Respiratory System. In: An Introduction to Cystic Fibrosis: For Patients and Their Families. 6th ed. Cystic Fibrosis Foundation; 2013:41-58.
  • Li Z, Kosorok MR, Farrell PM, et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA. 2005; 293(5):581-588.
  • Saiman L, Siegel JD, LiPuma JJ, et al. Infection prevention and control guideline for cystic fibrosis: 2013 update. Infect Control Hosp Epidemiol. 2014;35 Suppl 1:S1-S67. doi:10.1086/676882
  • Cystic fibrosis. Mayo Clinic website. Accessed June 1, 2021. https://www.mayoclinic.org/diseases-conditions/cystic-fibrosis/diagnosis-treatment/drc-20353706
  • Bacteria and Antibiotic Resistance In People with Cystic Fibrosis. Cystic Fibrosis Foundation website. Accessed June 1, 2021. https://www.cff.org/PDF-Archive/Bacteria-and-Antibiotic-Resistance-in-People-With-CF
  • Svedberg M, Gustafsson P, Tiddens H, Imberg H, Pivodic A, Lindblad A. Risk factors for progression of structural lung disease in school-age children with cystic fibrosis. J Cyst Fibros. 2020;19(6):910-916. doi:10.1016/j.jcf.2019.10.014
  • Calthorpe RJ, Smith SJ, Rowbotham NJ, et al. What effective ways of motivation, support and technologies help people with cystic fibrosis improve and sustain adherence to treatment? BMJ Open Respir Res. 2020;7(1):e000601. doi:10.1136/bmjresp-2020-000601
  • Bregnballe V, Schiøtz PO, Boisen KA, Pressler T, Thastum M. Barriers to adherence in adolescents and young adults with cystic fibrosis: a questionnaire study in young patients and their parents. Patient Prefer Adherence. 2011;5:507-515. doi:10.2147/PPA.S25308
  • Bishay LC, Sawicki GS. Strategies to optimize treatment adherence in adolescent patients with cystic fibrosis. Adolesc Health Med Ther. 2016;7:117-124. doi:10.2147/AHMT.S95637
  • Zobell JT, Moss J, Heuser S, Roe L, Young DC. Understanding the expanding role of pharmacy services in outpatient cystic fibrosis care. Pediatr Pulmonol. 2021;56(6):1378-1385. doi:10.1002/ppul.25283

Do you have questions about Pseudomonas aeruginosa?

Build your doctor discussion guide

You are about to leave FightPseudomonas.com

By following this link you are leaving this Gilead property. FightPseudomonas.com offers links to external pages, and Gilead is not responsible for any content published on the third-party website you are about to enter. Gilead has not reviewed and does not endorse any information presented on third-party websites.

You are leaving FightPseudomonas.com.

You will be directed to a product website to learn more about a treatment option for CF patients with Pseudomonas aeruginosa.

If you would like to continue to the site, select “OK.” If you do not wish to leave this site, select “Cancel.”